Book Description
The Authoritative Source of FDA-Approved Information on Prescription Drugs. Physicians have turned to PDR® for the latest word on prescription drugs for 59 years! Today, PDR is considered the standard prescription drug reference and can be found in virtually every physician's office, hospital and pharmacy in the United States. In fact, nine out of ten doctors consider PDR their most important reference source. The 59th edition is more than 3,000 pages—our most comprehensive edition ever! These critical new drugs are included in the 2005 edition: Cialis (tadalafil), a new selective inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase type 5 indicated for the treatment of erectile dysfunction. Crestor (rosuvastatin calcium), a new HMG-CoA reductase inhibitor indicated as an adjunct to diet in the treatment of primary hypercholesterolemia, mixed dyslipidemia, and elevated triglyceride levels, or as an adjunct to other lipid-lowering therapies (or if these are unavailable) for treatment of homozygous familial hypercholesterolemia. Levitra (vardenafil HCl), a new selective inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase type 5 indicated for the treatment of erectile dysfunction. Lexiva (fosamprenavir calcium), a new protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV infection in adults. Namenda (memantine HCl), the first NMDA receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer's type. Raptiva (efalizumab), a new recombinant humanized IgG1 kappa isotype monoclonal antibody indicated for the treatment of adults with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Symbyax (olanzapine and fluoxetine HCI), a new combination of 2 psychotropic agents for the treatment of depressive episodes associated with bipolar disorder. You'll find the most complete data on over 4,000 drugs by brand and generic name (both in the same convenient index), manufacturer, and product category. Your 2005 PDR provides usage information and warnings, drug interactions, plus more than 2,000 full-size, full-color photos cross-referenced to the product information. You will also find: >Phonetic spelling for most listings >A key to controlled substances >FDA use-in-pregnancy ratings >Contraindications >All other FDA-required information >Clinical pharmacology >Adverse reactions >Pediatric use >Dosages On average, over 70% of the drugs found in PDR have prescribing information that has been updated from that found in the previous years' edition. This means that each year thousands of changes are made to drugs. Among these changes are: >Interactions with other drugs >Side Effects >Recommended Dosages >Contraindications >Black box warnings >How supplied methods FREE PDR ELECTRONIC LIBRARY ON CD-ROM INCLUDED WITH THE 2005 PDR*! The retail edition of the 2005 PDR includes a free PDR Electronic Library on CD-ROM. This valuable CD-ROM includes the full-text information of the 2005 Physicians Desk Reference, PDR For Nonprescription Drugs and Dietary Supplements and the PDR For Ophthalmic Medicines. As an added bonus, the PDR on CD-ROM also includes a Drug Interactions module that allows the user to check multi-drug regimens for potentially dangerous interactions. That’s over $280 worth of print information on one CD-ROM. The 2005 PDR also includes important information on how authorized prescribers (including U.S.-based MDs, DOs, Dentists, NPs, PAs, Nurse Midwives, Nurse Anesthetists, and Clinical Nurse Specialists in full-time patient practice and medical students and residents) can access: >mobilePDR, PDR's abbreviated drug information database for PDR applications >drug information on PDR.net *Due to the importance of having current drug information, the PDR Electronic Library has a two year useful life. The software and data on this CD will expire on 12/31/06. For absolutely accurate information, you need the 2005 PDR!

Book Info
Brandon/Hill Medical List, minimal-core, first-purchase selection (#519). Annual reference provides Food and Drug Administration approved labeling for drugs as well as prescription information provided by manufacturers for grandfathered drugs and other drugs marketed without FDA approval. Some dietary supplements and other products are also included.

FROM THE PUBLISHER

The Authoritative Source of FDA-Approved Information on Prescription Drugs.

Physicians have turned to PDR® for the latest word on prescription drugs for 59 years! Today, PDR is considered the standard prescription drug reference and can be found in virtually every physician's office, hospital and pharmacy in the United States. In fact, nine out of ten doctors consider PDR their most important reference source. The 59th edition is more than 3,000 pages-our most comprehensive edition ever!

These critical new drugs are included in the 2005 edition:

Cialis (tadalafil), a new selective inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase type 5 indicated for the treatment of erectile dysfunction.
Crestor (rosuvastatin calcium), a new HMG-CoA reductase inhibitor indicated as an adjunct to diet in the treatment of primary hypercholesterolemia, mixed dyslipidemia, and elevated triglyceride levels, or as an adjunct to other lipid-lowering therapies (or if these are unavailable) for treatment of homozygous familial hypercholesterolemia.
Levitra (vardenafil HCl), a new selective inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase type 5 indicated for the treatment of erectile dysfunction.
Lexiva (fosamprenavir calcium), a new protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV infection in adults.
Namenda (memantine HCl), the first NMDA receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer's type.
Raptiva (efalizumab), a new recombinant humanized IgG1 kappa isotype monoclonal antibody indicated for the treatment of adults with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Symbyax (olanzapine and fluoxetine HCI), a new combination of 2 psychotropic agents for the treatment of depressive episodes associated with bipolar disorder.

You'll find the most complete data on over 4,000 drugs by brand and generic name (both in the same convenient index), manufacturer, and product category. Your 2005 PDR provides usage information and warnings, drug interactions, plus more than 2,000 full-size, full-color photos cross-referenced to the product information.

You will also find: Phonetic spelling for most listings A key to controlled substances FDA use-in-pregnancy ratings Contraindications All other FDA-required information Clinical pharmacology Adverse reactions Pediatric use Dosages On average, over 70% of the drugs found in PDR have prescribing information that has been updated from that found in the previous years' edition. This means that each year thousands of changes are made to drugs. Among these changes are: Interactions with other drugs Side Effects Recommended Dosages Contraindications Black box warnings How supplied methods FREE PDR ELECTRONIC LIBRARY ON CD-ROM INCLUDED WITH THE 2005 PDR*!

The retail edition of the 2005 PDR includes a free PDR Electronic Library on CD-ROM. This valuable CD-ROM includes the full-text information of the 2005 Physicians Desk Reference, PDR For Nonprescription Drugs and Dietary Supplements and the PDR For Ophthalmic Medicines. As an added bonus, the PDR on CD-ROM also includes a Drug Interactions module that allows the user to check multi-drug regimens for potentially dangerous interactions. That's over $290 worth of print information on one CD-ROM.

The 2005 PDR also includes important information on how authorized prescribers (including U.S.-based MDs, DOs, Dentists, NPs, PAs, Nurse Midwives, Nurse Anesthetists, and Clinical Nurse Specialists in full-time patient practice and medical students and residents) can access: mobilePDR, PDR's abbreviated drug information database for PDR applications drug information on PDR.net *Due to the importance of having current drug information, the PDR Electronic Library has a two-year useful life. The software and data on this CD will expire on 12/31/06.

For absolutely accurate information, you need the 2005 PDR!

SYNOPSIS

The Authoritative Source of FDA-Approved Information on Prescription Drugs.Physicians have turned to PDR￯﾿ﾽ for the latest word on prescription drugs for 59 years! Today, PDR is considered the standard prescription drug reference and can be found in virtually every physician's office, hospital and pharmacy in the United States. In fact, nine out of ten doctors consider PDR their most important reference source. The 59th edition is more than 3,000 pages-our most comprehensive edition ever!

These critical new drugs are included in the 2005 edition:

Cialis (tadalafil), a new selective inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase type 5 indicated for the treatment of erectile dysfunction. Crestor (rosuvastatin calcium), a new HMG-CoA reductase inhibitor indicated as an adjunct to diet in the treatment of primary hypercholesterolemia, mixed dyslipidemia, and elevated triglyceride levels, or as an adjunct to other lipid-lowering therapies (or if these are unavailable) for treatment of homozygous familial hypercholesterolemia. Levitra (vardenafil HCl), a new selective inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase type 5 indicated for the treatment of erectile dysfunction. Lexiva (fosamprenavir calcium), a new protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV infection in adults. Namenda (memantine HCl), the first NMDA receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer's type. Raptiva (efalizumab), a new recombinant humanized IgG1 kappa isotype monoclonal antibody indicated for the treatment of adults with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Symbyax (olanzapine and fluoxetine HCI), a new combination of 2 psychotropic agents for the treatment of depressive episodes associated with bipolar disorder. You'll find the most complete data on over 4,000 drugs by brand and generic name (both in the same convenient index), manufacturer, and product category. Your 2005 PDR provides usage information and warnings, drug interactions, plus more than 2,000 full-size, full-color photos cross-referenced to the product information.

You will also find: -Phonetic spelling for most listings -A key to controlled substances -FDA use-in-pregnancy ratings -Contraindications -All other FDA-required information -Clinical pharmacology -Adverse reactions -Pediatric use -Dosages

On average, over 70% of the drugs found in PDR have prescribing information that has been updated from that found in the previous years' edition. This means that each year thousands of changes are made to drugs. Among these changes are:

-Interactions with other drugs -Side Effects -Recommended Dosages -Contraindications -Black box warnings -How supplied methods

FREE PDR ELECTRONIC LIBRARY ON CD-ROM INCLUDED WITH THE 2005 PDR*! The retail edition of the 2005 PDR includes a free PDR Electronic Library on CD-ROM. This valuable CD-ROM includes the full-text information of the 2005 Physicians Desk Reference, PDR For Nonprescription Drugs and Dietary Supplements and the PDR For Ophthalmic Medicines. As an added bonus, the PDR on CD-ROM also includes a Drug Interactions module that allows the user to check multi-drug regimens for potentially dangerous interactions. That's over $290 worth of print information on one CD-ROM. The 2005 PDR also includes important information on how authorized prescribers (including U.S.-based MDs, DOs, Dentists, NPs, PAs, Nurse Midwives, Nurse Anesthetists, and Clinical Nurse Specialists in full-time patient practice and medical students and residents) can access:

-mobilePDR, PDR's abbreviated drug information database for PDR applications -drug information on PDR.net

*Due to the importance of having current drug information, the PDR Electronic Library has a two-year useful life. The software and data on this CD will expire on 12/31/06.